IMRN - Immuron Limited

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Immuron Limited

62 Lygon Street
Level 3
Carlton South, VIC 3053
61 3 9824 5254

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Gary S. JacobCEO & Non-Exec. DirectorN/AN/A1947
Mr. Peter AnastasiouExec. Vice ChairmanN/AN/A1960
Dr. Jerry Kanellos Ph.D.Chief Operating OfficerN/AN/A1961
Mr. Phillip Allen HainsCFO & Company Sec.N/AN/A1959
Mr. David LyonHead of MarketingN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company markets Travelan for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease; and IMM-529, a clinical stage product for clostridium difficile infections. The company has a research collaboration with the United States Department of Defense to develop and clinically evaluate a therapeutic against campylobacter. Immuron Limited was founded in 1994 and is based in Carlton South, Australia.

Corporate Governance

Immuron Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.